Posted on Sunday 1st July 2012
Dr Pamela Kearns has been appointed as the new Director of the Cancer Research UK Clinical Trials Unit (CRCTU) at Birmingham University, following the retirement of Professor Philip Johnson.
CRCTU is one of the largest cancer trials units in the UK and a member of the Birmingham Centre for Clinical Trials. The CRCTU is also an integral part of the Birmingham Experimental Cancer Medicine Centre and the Birmingham Cancer Research UK Cancer Centre. The unit receives core funding from Cancer Research UK.
Pamela Kearns is a Senior Lecturer in Paediatric Oncology in the School of Cancer Sciences and is an Honorary Consultant Paediatric Oncologist at the Birmingham Children’s Hospital. She also has responsibility for the Children’s Cancer Trials Team who are the designated lead for the UK’s National Portfolio of clinical trials for paediatric cancer and leukaemia.
"It will be a challenge to follow in Professor Johnson's footsteps but I am looking forward to further developing CRCTU's outstanding reputation. As we move into financially challenging times, I am committed to achieving the CRCTU's overall goal of scientific excellence in clinical trials with outputs that improve the quality of patient care".
Dr Pamela Kearns